Equities Analysts Issue Forecasts for KALV FY2026 Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Stock analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of KalVista Pharmaceuticals in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the specialty pharmaceutical company will post earnings per share of ($3.62) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share.

KALV has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. Bank of America initiated coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price objective on the stock. Finally, TD Cowen initiated coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price objective on the stock. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, KalVista Pharmaceuticals presently has an average rating of “Buy” and an average price target of $25.00.

KalVista Pharmaceuticals Stock Up 2.2 %

Shares of NASDAQ KALV opened at $8.75 on Wednesday. The firm’s 50-day moving average price is $8.90 and its 200-day moving average price is $11.08. The company has a market cap of $432.43 million, a PE ratio of -2.40 and a beta of 0.86. KalVista Pharmaceuticals has a 52-week low of $7.30 and a 52-week high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.01.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 8,077 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $74,793.02. Following the transaction, the insider now owns 94,199 shares of the company’s stock, valued at $872,282.74. The trade was a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Benjamin L. Palleiko sold 14,400 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $133,344.00. Following the transaction, the chief executive officer now directly owns 266,598 shares in the company, valued at $2,468,697.48. This represents a 5.12 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,291 shares of company stock valued at $304,086 over the last 90 days. 10.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of KALV. Vestal Point Capital LP raised its position in shares of KalVista Pharmaceuticals by 73.9% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock valued at $46,320,000 after buying an additional 1,700,000 shares during the last quarter. Great Point Partners LLC bought a new stake in shares of KalVista Pharmaceuticals during the second quarter valued at approximately $15,768,000. State Street Corp raised its position in shares of KalVista Pharmaceuticals by 68.1% during the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock valued at $14,725,000 after buying an additional 515,179 shares during the last quarter. Emerald Advisers LLC raised its position in shares of KalVista Pharmaceuticals by 29.8% during the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock valued at $9,681,000 after buying an additional 192,091 shares during the last quarter. Finally, Readystate Asset Management LP bought a new stake in shares of KalVista Pharmaceuticals during the third quarter valued at approximately $2,084,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).